BURST Expert Illustrations & Commentaries™: A Closer Look at the Role of Complement Inhibitors in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
April 28, 2023
April 28, 2024
Bleeding Disorders, Genetic Disorders
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is directed toward hematologists. Specialty nurse practitioners, physician assistants, and other health care practitioners involved in the management of patients with PNH are invited to participate.
This Burst Expert Illustrations and Commentaries™ is a blend of modular education through a text-and-audio format, including a video animation, to provide an overview of current and emerging management strategies for patients with paroxysmal nocturnal hemoglobinuria (PNH). In this program, an expert faculty provides commentary on the etiology and management of PNH using a case-based approach and focuses on the pathophysiology and current and emerging therapeutic strategies for PNH management. The activity is enriched with the use of video animation to illustrate the mechanism of action of complement inhibition therapy and its role in PNH management. The use of the animated segment helps make somewhat complicated subject matter more easily understood. This unique format is designed to help clinicians identify best practices in the diagnosis and management of PNH and to improve outcomes for their patients with this disease.
Upon completion of this activity, participants should be better able to:
- Describe the mechanisms of action of novel therapies used in the management of patients with PNH
- Design evidence-based treatment plans for patients with PNH
Ilene Ceil Weitz, MD
Professor of Clinical Medicine
Jane Anne Nohl Division of Hematology
Keck School of Medicine
University of Southern California
Los Angeles, CA
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
- Ilene Ceil Weitz, MD
- Consultant: Alexion Pharmaceuticals, Apellis-Sobi, Novartis
- Speaker’s Bureau: Alexion Pharmaceuticals
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
You may immediately download your certificate.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.